Compare Adaptive Biotechnologies Corp (ADPT) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs OneSpan Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while OneSpan Inc trades at $16.21 (market cap $600.69M). The key difference: Adaptive Biotechnologies Corp is far larger — about 6.7× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | OSPN | |
|---|---|---|
Market Cap | $4.04B | $600.69M |
Sector | Health | Technology |
52-Week High | $25.45 | $16.78 |
52-Week Low | $12.30 | $10.15 |
Enterprise Value | $4.10B | $569.77M |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
OneSpan (OSPN) trades at $16.21, down 0.98% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 9.21, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed revenue growth and raised full-year guidance, while the company continues paying $0.13 quarterly dividends.
Outlook remains positive with 67% analyst buy ratings and $17 consensus target offering 5% upside. Key risks include declining net cash flow and competitive pressures in the software sector. The stock presents value opportunity given attractive valuation multiples and strong profitability metrics, though investors should monitor execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
